APOB and metabolic syndrome: While childhood data regarding apoB’s and non-HDL cholesterol’s utility remains limited, preliminary findings hint at their potential to bolster current and future ASCVD risk prediction [63–68], especially among those with obesity-associated dyslipidemia characterized by hypertriglyceridemia and low HDL cholesterol [69].